Orion Animal Health Secures FDA Nod for Anxiety Treatment in Dogs
Event summary
- Orion Animal Health received FDA approval on May 6, 2026, for Tessie® (tasipimidine oral solution) to treat noise aversion and separation anxiety in dogs.
- Tasipimidine is a proprietary molecule acting on the central nervous system to block the startle reflex.
- Zoetis holds exclusive U.S. marketing rights and expects to launch Tessie® by mid-2027.
- The approval expands Orion’s portfolio of veterinary medicines addressing clinical needs.
The big picture
Orion’s FDA approval for Tessie® strengthens its position in the veterinary behavioral health space, a growing segment driven by increased pet ownership and demand for specialized treatments. The partnership with Zoetis, the world’s leading animal health company, ensures broad market reach. This approval aligns with Orion’s strategy of leveraging scientific innovation to address unmet clinical needs in companion animals.
What we're watching
- Market Positioning
- How Tessie® will compete against Zoetis’s existing behavioral products, Sileo® and Bonqat®, in the U.S. market.
- Commercial Execution
- The pace at which Zoetis can integrate and market Tessie® alongside its current portfolio.
- Regulatory Expansion
- Whether Orion will seek approvals for tasipimidine in other regions beyond the U.S.
Related topics